We conduct and support substance use research to inform evidence-based care and improve patient health and treatment outcomes. In addition to providing data and guidance to CODA, the program publishes in peer-reviewed journals, presents at national and international conferences, and participates in federally and privately funded research.

CODA research

CODA’s nationally recognized Research Program has randomized over 2,000 study participants in 20 funded trials. We have collaborated with Oregon Health & Science University (OHSU), Geisel School of Medicine at Dartmouth College, University of Pittsburgh, University of Washington, Virginia Commonwealth University, Kaiser Permanente, and other institutions on research funded by the National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), and other foundations and companies. Earlier clinical trials examined the use of extended-release naltrexone and buprenorphine, leading CODA to be early adopters of these FDA-approved medications for opioid use disorders.

CODA Conference Presentations

CODA Research Publications

Current studies

Accelerated Development of Additive Pharmacotherapy for the Treatment of Methamphetamine Use Disorder (ADAPT-2)

CODA Methamphetamine Use Disorder Study

Know of someone who wants to reduce or stop using meth? Do you want to stop?

Currently, CODA Research is recruiting for a medication trial to treat methamphetamine use disorder.

There are no FDA approved medications for methamphetamine use disorder – this trial hopes to change that.

Call or text 503-309-3841 to or email research@codainc.org for more information.

Study description

Reducing Risk of Overdose After Release From Incarceration (ROAR)

Drug overdose is the leading cause of death after release from prison, and this risk is significantly higher among women compared to men. We will pilot and evaluate the cross-disciplinary opioid overdose prevention program “Reducing Overdose After Release from Incarceration” (ROAR) at Oregon’s Coffee Creek Correctional Facility. ROAR combines provision of medications for treatment of substance use disorders with support from Certified Recovery Mentors and linkage to long-term treatment in community. We will assess reduced risk of fatal and non-fatal opioid overdose among adult women released from prison using linked administrative data from Oregon’s Department of Corrections, Health Authority and Office of Forecasting, Research and Analysis.

About our studies

CODA Research generally participates in two types of studies:

  • Surveys about your opinions, beliefs, or practices
  • Clinical trials

Participants in any clinical trial are chosen based on eligibility. The informed consent process provides participants with clear explanations of your rights and risks prior to joining a research study.

To learn more about current studies, call or text 503-309-3841 or email research@codainc.org for more information.

Learn More

Important things to know about our studies:

Medications or components of medications used in trials are usually FDA approved. Often, the research is testing a new application of a medication or a new combination of medications.

Compensation is always provided to research participants and is usually provided in the form of a gift card to a food/retail chain. The amount of compensation varies with the research project.

Your participation and personal information is confidential.